Veracyte (VCYT)
(Real Time Quote from BATS)
$19.53 USD
-0.37 (-1.86%)
Updated Apr 25, 2024 12:51 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VCYT 19.53 -0.37(-1.86%)
Will VCYT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VCYT
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Medical Instruments Stocks to Buy as Industry Trends Improve
The Zacks Analyst Blog Highlights Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath
5 Top-Ranked Cathie Wood Stocks to Buy Right Now
Other News for VCYT
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Veracyte study shows Decipher Prostate Test is prognostic
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024